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clearance times for AL, ASAQ and AQC were comparable
(p = 0.94 and p = 0.122, respectively). On day 14, the ade-
quate clinical and parasitological response (ACPR) for AL and 
AQC was 100% and for ASAQ it was 90% (p = 0.39). The PCR-
uncorrected results on days 28 and 42 and the ACPR-correct-
ed results on day 42 were similar for all drugs (p = 0.62 and 
p = 0.56, respectively). AQC resulted in the best parasite 
clearance and haematological recovery on day 2 (p = 0.022 
and p = 0.018, respectively). Biochemical parameters were 
not adversely affected by the three artemisinin-based com-
bination therapies (ACTs) and these were well tolerated. 
 Conclusion: The three ACTs were efficacious and safe, but 
AQC resulted in a better haematological recovery on day 2 
and higher cure rates throughout the study period. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Artemisinin-based combination therapy (ACT), 
which was first recommended by the World Health Or-
ganization (WHO) in 2001, has become widely accepted 
as the best option for the treatment of acute uncompli-
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 Abstract 
 Objective: To evaluate the comparative efficacy and safety 
of artemether-lumefantrine (AL), artesunate-amodiaquine 
(ASAQ) and artesunate-amodiaquine-chlorpheniramine 
(AQC) for the treatment of acute uncomplicated malaria 
among Southwest Nigerian children.  Subjects and Methods: 
One hundred and sixty children aged 6 months to 14 years 
with acute uncomplicated malaria were randomized to AL
(n = 53), ASAQ (n = 53), or AQC (n = 54). Enrollees were seen 
daily on days 0–3 and then on days 7, 14, 21, 28 and 42 for 
clinical and parasitological evaluations. Paired samples of 
genomic DNA at enrolment and at the time of recurrent par-
asitaemia were genotyped using nested PCR to distinguish 
between reinfection and recrudescence. Detailed haemato-
logical and biochemical evaluations were carried out in a 
subset of enrollees on days 0, 7 and 28 as part of a safety 
evaluation.  Results: Of the 160 children, 144 (90%) complet-
ed the study. The mean fever clearance times and parasite 
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cated falciparum malaria  [1] . ACTs have been widely ac-
cepted because of their efficacy against falciparum infec-
tions of varying sensitivities  [2–5] . The rapid schizontici-
dal effect of artemisinin derivatives, combined with the 
schizonticidal effect of another efficacious longer-acting 
anti-malarial drug with a different mechanism of action, 
forms the basis for the sustained efficacy of ACTs. How-
ever, companion drugs for ACTs are few and limited. 
Amodiaquine in combination with artesunate is one of 
the preferred ACTs recommended by the WHO and has 
been adopted as the drug of choice for the treatment of 
acute uncomplicated falciparum malaria in some coun-
tries  [3] . Lumefantrine, mefloquine, piperaquine and sul-
fadoxine-pyrimethamine are other recommended com-
panion drugs in ACT  [3] .
 Amodiaquine in combination with chlorpheniramine 
has been reported to be significantly more effective than 
amodiaquine alone for the treatment of acute uncompli-
cated falciparum malaria  [6, 7] . This is most probably due 
to the enhancement of the anti-malarial effect of amodia-
quine by chlorpheniramine. The combination of amodi-
aquine-chlorpheniramine could be a better alternative to 
amodiaquine alone as a companion drug in ACT as chlor-
pheniramine would act as a resistance modulator should 
there be mild amodiaquine resistance.
 Nigeria adopted ACT as the therapeutic regimen of 
choice for the treatment of acute uncomplicated falci-
parum malaria, with artemether-lumefantrine (AL) and 
artesunate-amodiaquine (ASAQ) as the preferred op-
tions, in 2005  [8] . Artemoclo TM is a new fixed-dose for-
mulation of artesunate-amodiaquine plus chlorphenira-
mine. Chlorpheniramine has been added to artesunate 
plus amodiaquine in Artemoclo as a resistance modulator 
to enhance the efficacy of amodiaquine as resistance 
could limit the efficacy of amodiaquine. In this report, we 
present the findings of a study which evaluated the com-
parative efficacy and safety of AL, ASAQ and artesunate-
amodiaquine-chlorpheniramine (AQC) for the treat-
ment of acute uncomplicated falciparum malaria.
 Subjects and Methods 
 Study Location 
 The study reported here is the Ibadan part of a multi-centre 
study designed to assess the comparative efficacy and safety of AL, 
ASAQ and AQC for the treatment of acute uncomplicated ma-
laria in 4 of 6 geopolitical zones in Nigeria, i.e. southwest (Ibadan), 
north-central (Ilorin), northwest (Kaduna) and southeast (Enu-
gu). The Ibadan study was conducted at the General Outpatient 
Department of the University College Hospital (UCH), Ibadan, 
and the Primary Health Care Center (PHC), Idi-Ayunre, Oluyole 
Local Government Area. The Idi-Ayunre PHC is located 20 km 
from the city of Ibadan and serves 5–6 villages around it. Both the 
UCH and the Idi-Ayunre PHC are located in the rain forest belt of 
Southwest Nigeria. Malaria transmission is perennial in the study 
area, with peak transmission occurring during the months of the 
rainy season (May to October) and a nadir in the months of the dry 
season (November to April). Enrolment into this study was ex-
tended to the rural PHC because, unlike in the past, it was difficult 
to find patients who satisfied the enrolment criteria fast enough at 
the UCH centre. One hundred and sixty subjects were enrolled 
into this study.
 Ethical Issues 
 This study was conducted according to Good Clinical Practice 
and the Declaration of Helsinki. The University of Ibadan/UCH 
Institutional Review Committee approved this study. Written or 
witnessed verbal informed consent was obtained from the parent 
or guardian of each child.
 Study Design 
 The study design was an open-labelled comparison of AL, 
ASAQ and AQC. Inclusion criteria were: children aged 1–14 years 
of either sex with microscopically confirmed  Plasmodium falci-
parum malaria, asexual parasite density  ≥ 1,000/μl, axillary tem-
perature  ≥ 37.5  °  C or a history of fever in the preceding 48 h, symp-
toms compatible with acute uncomplicated malaria and provision 
of signed informed consent by the parent or guardian. Exclusion 
criteria were: children with signs of severe malaria such as im-
paired consciousness, multiple convulsions or coma  [3] , concom-
itant illness or malnutrition, other causes of fever, severe anaemia 
(haematocrit <15%), a history of hypersensitivity to any of the 
study drugs and a history of anti-malarial drug use, except for chlo-
roquine or sulfadoxine-pyrimethamine, in the 7 days preceding 
study.
 A power calculation with an α level of significance at 5% showed 
a minimum sample size of 143, but 160 subjects were enrolled into 
this study. The enrolled children were randomly allocated to one 
of three groups to receive one of the three ACTs according to a 
pre-generated randomization table. A randomization table was 
generated in blocks of 10 using a table of random numbers. The 
study participants were allocated to the respective drug groups by 
the study nurse who was also responsible for administering the 
drugs under supervision at the clinic. The subjects were enrolled 
from August 2007 to May 2008. Fifty-three subjects, respectively, 
were randomized to receive AL and ASAQ while 54 received AQC. 
A research assistant administered the second daily dose of AL at 
home. Physicians and microscopists who were responsible for pa-
tient follow-up and slide examination were, however, blinded to 
the individual patient treatment group allocation. Children who 
developed serious adverse events, suffered recurrent vomiting af-
ter redosing or violated the protocol or whose parent/guardian re-
tracted consent were withdrawn from the study.
 Children treated with AL received a 6-dose regimen of AL (Co-
artem TM ; Novatis Pharma) at a standard weight-based dosage as 
follows: 5 to <15 kg, 1 tablet twice daily for 3 days; 15 to <25 kg:
2 tablets twice daily for 3 days, and 25 to <35 kg: 3 tablets twice 
daily for 3 days. Children in the ASAQ group received artesu-
nate – 4 mg/kg to the nearest next quarter of a tablet – plus amo-
diaquine (Camoquine; Pfizer Ltd.) at a dose of 10 mg/kg, while 
children in the AQC group received a fixed-dose formulation of 
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AQC in the form of Artemoclo manufactured by Neimeth Phar-
maceuticals under good manufacturing practices. Each tablet of 
AQC contains 100 mg artesunate, 300 mg amodiaquine and 4 mg 
chlorpheniramine. The amodiaquine component was used as the 
reference for dosing at a dose of 10 mg/kg to the nearest next quar-
ter of a tablet.
 Pre-Treatment 
 A thorough medical history, a physical examination including 
vital signs, a specific neurological examination and baseline signs 
and symptoms of malaria for a safety evaluation of treatment-
emergent signs and symptoms were carried out. Blood samples for 
definitive parasite counts and haematocrit evaluations were done 
at every visit. Pre-treatment blood spots for PCR evaluation were 
also prepared from each enrollee for subsequent genotyping of 
malaria parasites in case of a recurrence of parasitaemia after the 
initial clearance. Venous blood was obtained from a subset of study 
volunteers for detailed haematological and biochemical evalua-
tions. The haematological evaluation included haematocrit, hae-
moglobin, red blood cell counts and white blood cell counts with 
differential and platelet counts. Blood chemistry parameters in-
cluded bilirubin, creatinine, alanine transaminase and aspartate 
transaminase. All parameters were recorded in a case record form 
specifically provided for this purpose.
 Study Drug Administration 
 Older children swallowed the study drug whole with water, 
while younger children less than 4 years of age received the drug 
crushed and mixed with water. Parents and guardians were asked 
to feed children who received AL a fat-containing meal soon after 
dosing to enhance absorption. The children were observed for 1 h 
to ensure that the study drug was not vomited. Any patient who 
vomited the study drug within 1 h received the same dose of the 
drug again and was observed for vomiting as with the initial dos-
ing.
 Patient Follow-Up 
 Patients were seen daily on an outpatient basis from day 0 to 
day 3 and then on days 7, 14, 21 and 28. Parents were encouraged 
to bring their children in for follow-up on day 42. The axillary tem-
perature, pulse rate and treatment-emergent signs and symptoms 
were evaluated and a blood film for malaria parasite evaluation was 
carried out at each follow-up visit in the clinic or at home for those 
who missed the follow-up appointment. Parents/guardians were 
also encouraged to bring their children to the clinic whenever there 
was a need for medical attention even if this was outside of their 
appointment days. The therapeutic response was assessed using 
clinical and parasitological parameters. Blood spots were blotted 
on Whatman TM filter paper for PCR at the recurrence of parasitae-
mia for the genotyping of isolates to distinguish between recrudes-
cence and reinfection. In addition, haematology and blood chem-
istry evaluations were repeated on days 7 and 28 for patients ran-
domized to detailed haematology and blood chemistry evaluations. 
Giemsa-stained blood films prepared from a finger prick at each 
visit were examined under an oil immersion objective at ×1,000 
magnification for parasite detection, quantification and morphol-
ogy. The parasite density was estimated in thick films by counting 
the number of asexual parasites relative to about 200 leucocytes. 
The definitive parasite density was calculated using an assumed 
white blood cell count of 8,000/mm 3 .
 Efficacy Evaluation 
 Study outcomes were classified as early treatment failure (ETF), 
late clinical failure (LCF), late parasitological failure (LPF) or ad-
equate clinical and parasitological response (ACPR)  [9] . ETF was 
defined as the development of danger signs of malaria or severe 
malaria on post-treatment day 1, 2 or 3 in the presence of parasi-
taemia, parasitaemia on day 2 higher than the day 0 count irrespec-
tive of the axillary temperature, parasitaemia on day three  ≥ 25% 
of the count on day 0 and parasitaemia on day 3 with an axillary 
temperature  ≥ 37.5  °  C. LCF was defined as the development of dan-
ger signs or severe malaria after day 3 in the presence of parasitae-
mia without previously meeting any of the criteria for ETF and 
presence of parasitaemia and an axillary temperature  ≥ 37.5  °  C on 
any day from day 4 to day 28 without previously meeting any of 
the criteria of ETF. LPF, on the other hand, was defined as the pres-
ence of parasitaemia on any day from day 7 to day 28 and an axil-
lary temperature <37.5   °   C without previously meeting any of the 
criteria for ETF or LCF. ACPR was defined as the absence of para-
sitaemia on day 28 irrespective of the axillary temperature without 
previously meeting any of the criteria for ETF, LCF or LPF. The 
cure rates on days 14, 28 and 42 were defined as the proportion of 
patients cleared of asexual parasitaemia within the specific time 
interval of the initiation of treatment with the respective study 
drug without recrudescence within the specified days. In addition 
to the cure rates, the mean fever clearance time (FCT), the mean 
parasite clearance time (PCT) and the proportion of patients 
cleared of patent parasitaemia at 24, 48 and 72 h following treat-
ment were determined. The PCT was defined as the time elapsing 
from drug administration and the clearance of patent parasitae-
mia, while the FCT was defined as the time from drug administra-
tion until the axillary temperature fell below 37   °   C and remained 
so for at least 48 h.
 Retreatment of Drug Treatment Failures 
 All patients in whom parasitaemia recurred following ASAQ or 
AQC treatment were retreated with AL, while those who had a re-
appearance of parasitaemia following AL treatment received 
ASAQ.
 Safety Evaluation 
 The safety assessment consisted of monitoring and recording 
all adverse events whether volunteered, discovered via questioning 
or detected by physical examination. Also included were clinically 
significant changes in the values of haematology and blood chem-
istry parameters.
 Molecular Genotyping 
 Genomic DNA was extracted from filter paper blood spots via 
the Chelex-100 method in a 96-well plate format as previously de-
scribed  [10] . Paired samples from every patient at enrolment and at 
the time of recurrence of parasitaemia were genotyped using a nest-
ed PCR amplification of the polymorphic regions of  P. falciparum 
genes  msp1 (K1, MAD20 and RO33) and  msp2 (IC1 and FC27) as 
described elsewhere  [11] . Samples (10 μl) of the nested PCR prod-
ucts were resolved on 2–2.5% agarose gels (Sigma-Aldrich) in 1× 
Tris-borate-EDTA buffer, stained with ethidium bromide and vi-
sualized via UV transillumination. If no alleles matched at any of 
the two genetic loci between day 0 and the day of recurrence, the 
infection was classified as a reinfection. If any allele was identical at 
any of the loci, the infection was classified as a recrudescence.
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 Data Analysis 
 All generated data were entered into the computer and anal-
ysed using Statistical Package for Social Sciences version 15.0 soft-
ware (SPSS Inc., Chicago, Ill., USA). The cure rates at the different 
time points were calculated as percentages. Efficacy analysis of the 
data was done for the intention-to-treat (ITT) and per-protocol 
(PP) populations. All of the children enrolled into the study were 
considered the ITT population. Patients who completed the study 
without violating the study protocol were considered the PP popu-
lation. The effect size and OR with 95% CI were used to measure 
the treatment effect for the main outcomes. The means ± SD of 
normally distributed data were compared using Student’s t test and 
ANOVA. Proportions were compared using χ 2 test. The results of 
haematology and liver enzymes over time were analysed using a 
paired t test comparing days 0 and 7 as well as days 0 and 28. Nu-
merical values are given as means ± SD, and p < 0.05 was consid-
ered statistically significant.
 Results 
 Patient Disposition and Demographic Data 
 The characteristics of the study participants in the 
three groups were comparable at entry. The details of the 
presenting symptoms of the study population are shown 
in  table 1 . The details of the baseline characteristics of the 
study patients at enrolment are shown in  table 2 . The 4 
most common presenting complaints were: fever, n = 160 
(100%); anorexia, n = 85 (53.5%); vomiting, n = 82 
(51.3%), and headache, n = 70 (44.3%). The study drugs 
were well tolerated. Three of 53 (5.7%), 4 of 53 (7.6%) and 
4 of 54 (7.4%) children treated with AL, ASAQ and AQC, 
respectively, vomited the study drug within 30 min of 
Presenting complaints  Treatment group, n (%) Total, n (%) p value
 AL ASAQ AQC
Fever 53 (100) 53 (100) 54 (100) 160 (100) –
Anorexia 24 (46.2) 29 (54.7) 32 (59.3) 85 (53.5) 0.391
Vomiting 28 (52.8) 28 (52.8) 26 (48.1) 82 (51.3) 0.692
Headache 15 (28.8) 27 (52.9) 28 (51.9) 70 (44.3) 0.023
Chills and rigors 21 (41.2) 23 (43.4) 25 (46.3) 69 (43.7) 0.869
Cough 19 (35.9) 18 (35) 21 (38.9) 58 (36.3) 0.701
Abdominal pain 11 (21.2) 18 (34.0) 12 (22.2) 41 (25.8) 0.247
Diarrhoea 9 (17.3) 9 (17.3) 7 (13.0) 25 (15.8) 0.777
Irritability 6 (11.5) 7 (13.7) 12 (9.3) 18 (11.5) 0.773
 Table 1.  Presenting complaints of children 
suffering from acute uncomplicated
malaria treated with AL, ASAQ or AQC 
in Nigeria
AL ASAQ AQC p value
Total, n 53 53 54
Sexa
Male 28 (52.8) 30 (56.6) 25 (46.3) 0.56b
Female 25 (47.2) 23 (43.4) 29 (53.7)
Age, months
Mean ± SD 49.28 ± 35.4 51.03 ± 32.77 52.08 ± 33.45 0.91c
Range 6 – 144 7 – 126 7 – 168
Weight, kg
Mean ± SD 14.38 ± 5.74 14.78 ± 5.46 14.69 ± 5.82 0.93c
Range 5 – 35 5 – 30 5 – 25
Temperature, oC 
Mean ± SD 37.68 ± 1.17 37.74 ± 1.06 37.41 ± 1.18 0.51c
Range 35.5 – 40.7 36.0 – 39.8 38.5 – 40.2
Parasite density, n/μl
Geometric mean 13,524 15,817 16,183 0.76c
Range 1,115 – 244,157 1,000 – 230,793 1,109 – 151,259
Haematocrit, %
Mean ± SD 30.4 ± 4.54 29.94 ± 6.48 30.70 ± 3.79 0.74c
Range 15 – 37 15 – 40 20 – 38
a n (%). b χ2 test. c One-way ANOVA.
 Table 2.  Baseline characteristics of
children suffering from acute
uncomplicated malaria treated with AL, 
ASAQ or AQC in Nigeria
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drug administration. In no patient was there a recurrence 
of vomiting after redosing and no patient was withdrawn 
as a result of recurrent vomiting. Of the 150 enrollees, 16 
(10.7%) did not complete the study. Of these 16, six (AL: 
n = 2; ASAQ: n = 3; AQC: n = 1) were lost to follow-up 
while 10 (AL: n = 6; AQC: n = 4) were withdrawn for 
various reasons. Reasons for withdrawal included proto-
col violations (AL: n = 3; AQC: n = 3), while 3 children 
(AL: n = 2; AQC: n = 1) were withdrawn because their 
parents retracted the consent they had provided earlier. 
The list of protocol violations included the administra-
tion of other anti-malarial drugs (n = 4) and a definitive 
parasite count below the cutoff value (n = 2). Two parents 
refused finger pricks for their children after day 3 when 
the children were fully recovered, while 1 parent travelled 
out of the study area and informed the study team. One 
child who was treated with AL was withdrawn because of 
a serious adverse event. The child convulsed at home 
about 18 h after enrolment. She had received 2 doses of 
AL before the seizure. She was taken to a private clinic in 
the community where she received intra-muscular and 
oral chloroquine and an anti-pyretic analgesic. She was 
free of patent parasitaemia by the end of day 2 when she 
was visited at home. She made an uneventful recovery 
 Table 3.  Treatment outcomes in Nigerian children suffering from acute uncomplicated malaria treated with AL, 
ASAQ or AQC
Characteristic AL ASAQ AQC p value
PP population (day 14) 
ACPR
LPF
45/45 (100)
–
49/50 (98)
1 (2)
49/49 (100)
–
0.388
ACPR (PCR uncorrected; day 28)
LPF
LCF
PCR-corrected cure rate
41/45 (91.1)
2 (4.4)
2 (4.4)
43/45 (95.6)
46/50 (92)
2 (4)
2 (4)
46/48 (95.8)
47/49 (95.9)
2 (4.1)
–
47/49 (95.9)
0.622
ACPR (PCR uncorrected; day 42)
LPF/LCF
PCR-corrected cure rate
28/38 (73.7)
10/38 (26.3)
32/38 (84.2)
32/40 (80.0)
8/40 (20.0)
34/37 (91.9)
32/37 (86.5)
5/37 (15.5)
35/37 (94.6)
0.555
ITT population
LPF (day 14)
ACPR 
53 (100)
7/53 (13.2)
46 (86.7)
53 (100)
4 (7.4)
49 (92.5)
54 (100)
4 (7.4)
50 (92.6)
0.504
LPF (day 28)
LCF 
ACPR
9 (17.6)
3 (5.7)
41 (77.4)
5 (9.4)
2 (3.8)
46 (86.8)
7 (13.0)
0 (0)
47 (87.0)
0.307
Mean FCT ± SD (range), days 1.21 ± 0.51 (1 – 3) 1.19 ± 0.48 (1 – 3) 1.16 ± 0.38 (1 – 2) 0.94
Mean PCT ± SD (range), days 2.1 ± 0.77 (1 – 4) 1.82 ± 0.66 (1 – 3) 1.85 ± 0.57 (1 – 3) 0.122
Presence of parasitaemia
Day 1
Day 2
Day 3
37/51 (72.5)
14/51 (27.5)
1/49 (2.04)
36/51 (70.6)
7/49 (14.3)
0%
36/52 (69.2)
3/49 (6.1)
0%
0.944
0.022
0.335
Presence of fever
Day 1
Day 2
Day 3
3/50 (6.0)
3/50 (6.0)
0 (0)
2/51 (3.8)
1/50 (2.0)
0/52 (0)
4/51 (7.8)
2/51 (3.9)
0/52 (0)
0.675
0.545
–
Mean haematocrit ± SD, %
Day 2
Day 14
Day 28
29.2 ± 4.9
32.3 ± 3.2
35 ± 4.0
27.2 ± 4.4
32.5 ± 4.2
35.1 ± 3.2
30.0 ± 4.8
33.0 ± 3.2
34.7 ± 3.0
0.018
0.803
0.787
Drowsiness
Day 1
Day 2
Day 3
5/52 (9.6)
1/51 (1.96)
2/51 (3.9)
6/53 (11.3)
5/53 (9.4)
2/53 (3.6)
35/53 (66.6)
18/53 (34.0)
4/53 (5.1)
<0.0001
<0.0001
0.608
Values are presented as n (%) unless indicated otherwise.
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and was followed up to day 28 for a safety evaluation. The 
6 children who were lost to follow-up and the 3 whose 
parents withdrew consent fully recovered and were free 
of patent parasitaemia when they were seen last.
 Outcome of Efficacy Evaluation 
 Of the 160 children who constituted the ITT popula-
tion, 144 (90%), i.e. AL, n = 45 (84.9%); ASAQ, n = 50 
(94.3%), and AQC, n = 49, completed the study as stipu-
lated by the protocol (PP population). There was no re-
cord of ETF during the study. The mean fever and PCT 
for AL, ASAQ and AQC were similar. The proportion of 
children who were cleared of patent parasitaemia on day 
2 (AL, 72.5%; ASAQ, 85.7%; AQC, 93.9%) was signifi-
cantly higher (p = 0.022) ( table 3 ) among those treated 
with AQC compared to AL and ASAQ. However, there 
was no significant difference in haematological recovery 
on days 14 and 28. All but 1 child who received AL were 
free of patent parasitaemia by day 3. The day 14 cure rate 
for AL and AQC was 100% while that for ASAQ was 
49/50 (98%). The ACPR (PCR uncorrected) day 28 values 
were 91.1% (41/45) for AL, 92% (46/50) for ASAQ and 
95.9% (47/49) for AQC. The PCR-adjusted cure rates for 
AL, ASAQ and AQC on day 28 were 95.6, 95.8 and 95.9%, 
respectively, while the figures for day 42 were 84.2, 91.9 
and 94.6% for AL, ASAQ and AQC, respectively. The 
higher ACPR of AQC on days 28 and 42 were not statisti-
cally significant. When compared with AL at day 28, the 
cure rate for ASAQ had an OR of 1.119 (95% CI 0.214–
5.347; p = 0.394) while that of AQC had an OR of 1.679 
(95% CI 0.267–10.537; p = 0.581). The day 42 values for 
ASAQ were: OR 1.292, 95% CI 0.437–3.817 and p = 0.643; 
those for AQC were: OR 1.133, 95% CI 0.638–7.134 and 
p = 0.219. Further details of the results of the efficacy eval-
uation are shown in  table 3 . 
 Outcome of the Safety Evaluation 
 Most of the recorded adverse events were signs and 
symptoms of malaria, thereby making their assessment 
difficult. Adverse events recorded among the study par-
ticipants (ITT population) were: fever, anorexia, vomit-
ing, abdominal pain, cough and drowsiness. Those who 
received AQC were significantly more drowsy on days 1 
(p < 0.0001) and 2 (p < 0.0001) ( table 3 ). No study par-
ticipant was withdrawn as a result of recurrent vomiting. 
The serum bilirubin was significantly higher on day 7 
compared to day 0 among children who received AL (p = 
0.003). The other paired tests conducted on blood chem-
istry and liver enzymes were not statistically different ( ta-
ble 4 ). Evidence of intra-vascular haemolysis was not de-
tected in any of the participants. The haematological re-
covery was good in the three treatment arms. There was 
an early superior statistically significant (p = 0.018) hae-
matological recovery among children who were treated 
with AQC compared to ASAQ and AL ( table 3 ). One case 
of an observed serious adverse event which occurred dur-
ing the study was not considered drug related.
 Table 4.  Blood chemistry and liver enzymes among children with acute uncomplicated malaria treated with AL, ASAQ or AQC
Blood chemistry parameters/LFT Day 0 Day 7 t value p value Day 28 t value p value
AL
Creatinine
Bilirubin
AST
ALT
0.878 ± 0.72
0.444 ± 0.17
11.0 ± 6.0
6.0 ± 4.183
0.850 ± 0.310
0.5 ± 0.080
15.75 ± 2.500
6.250 ± 3.304
0.868
–2.330
–9.127
–2.143
0.449
0.102
0.003
0.122
0.767 ± 0.197
0.533 ± 0.28
12.33 ± 5.85
8.167 ± 5.811
0.997
0.974
–1.830
–2.140
0.392
0.402
0.165
0.125
ASAQ
Creatinine
Bilirubin
AST
ALT
0.800 ± 0.6
0.467 ± 0.25
20.56 ± 10.38
10.556 ± 5.341
0.980 ± 0.669
0.650 ± 0.240
20.0 ± 12.460
10.556 ± 6.557
–0.670
1.000
2.000
0.670
0.705
0.156
0.295
0.958
1.264 ± 0.996
0.436 ± 0.163
20.0 ± 12.46
10.500 ± 6.557
0.371 
1.000
2.000
0.670
0.740
0.423
0.295
0.958
AQC
Creatinine
Bilirubin
AST
ALT
1.036 ± 0.693
0.655 ± 284
12.82 ± 6.06
14.364 ± 10.327
0.533 ± 0.250
0.583 ± 0.983
14.83 ± 5.9
17.333 ± 5.317
2.355
0.974
3.000
1.640
0.100
0.328
0.659
0.200
0.657 ± 0.230
0.500 ± 0.173
13.430 ± 8.460
11.00 ± 6.590
0.670
0.389
0.551
0.000
0.670
0.717
0.551
1.00
 Values are presented as means ± SD. AST = Aspartate amino transaminase; ALT = alanine amino transaminase.
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 Discussion 
 It is generally accepted that ACTs are the treatment of 
choice for acute uncomplicated malaria  [2–5, 12] . The 
three ACTs had similar efficacies but AQC was better 
than AL and ASAQ. The response to treatment was 
prompt in the three treatment arms without any record 
of ETF. In addition to high cure rates, most of the other 
parameters for assessing efficacy such as PCT and FCT 
were also comparable among children randomized to all 
three study drugs ( table 3 ). It is, however, noteworthy that 
the FCT and PCT in the present study were inaccurate 
measures because body temperature and parasite density 
were measured every 24 h from day 0 to day 3 and not 
every 6 or 8 h as in some other published studies  [2] . The 
overall health of the children in this study was good.
 A significantly higher proportion of children treated 
with AQC had parasitaemia clearance on day 2 compared 
to those who received AL and ASAQ. The haematological 
recovery was also significantly better on day 2 among 
children treated with AQC. The significantly better hae-
matological recovery on day 2 was most likely a confirma-
tion of the higher proportion of children cleared of patent 
parasitaemia on day 2. The full significance of this finding 
is still not clear. It could, however, be an indication of the 
enhancement of the anti-malarial effect of artesunate plus 
amodiaquine by chlorpheniramine. The failure to detect 
a statistically significant superiority in the cure rates of 
AQC over the others was probably related to the gener-
ally high efficacy of the three ACTs. The day 28 cure rates 
of 91.1, 92 and 95.9% for AL, ASAQ and AQC, respec-
tively, are consistent with the high cure rates in previous 
reports of ACT efficacy  [4, 5, 12–16] . The new combina-
tion of AQC, which is being evaluated for the first time, 
yielded the highest though not the most clinically signifi-
cant cure rate of the three study drugs at all evaluated time 
points. AQC also yielded significantly higher PCR-cor-
rected cure rates than AL on day 42. This is not surprising 
because amodiaquine, the companion drug to artesunate, 
in these combinations has a longer half-life than lumefan-
trine (the companion drug to AL), thus providing a lon-
ger post-treatment prophylaxis. As a corollary, the short-
er post-treatment prophylaxis by AL may also be respon-
sible for its relatively low day 42 cure rate. Many of the 
parasite recurrences on day 42 may actually have been 
reinfections which were misclassified as is often the case 
in areas where malaria transmission is intense  [17] .
 Reported adverse events included fever, cough, vomit-
ing and increased sleepiness. More children who received 
AQC were reported to have slept for significantly longer 
periods during the first 2 days of treatment than they usu-
ally did, and this could have been due to drowsiness, a 
well-known pharmacological effect of chlorpheniramine. 
This could also be beneficial for the recovery of the sick 
child. Drowsiness associated with AQC could, however, 
have adverse consequences for children while in school.
 Conclusion 
 This study confirmed the efficacy of ACTs for the 
treatment of acute uncomplicated malaria even in an area 
of established drug-resistant infection such as Nigeria. 
The fixed-dose combination of AQC could be another 
addition to the currently available artemisinin combina-
tions for the treatment of acute uncomplicated malaria, 
but evaluations with larger sample sizes are needed.
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